Newsfeeds - Spark Newswire

1 minute read

Analysts Believe Madrigal’s Resmetirom Shows Impressive Overall Profile In Liver Fibrosis

Today, 12:00 PM

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) presented multiple resmetirom abstracts at the European Association for the Study of the Liver’s International Liver Congress.…

MDGL

1 minute read

Oppenheimer Maintains Outperform on Madrigal Pharmaceuticals, Lowers Price Target to $170

By Benzinga Newsdesk

Today, 12:00 PM

Oppenheimer analyst Jay Olson maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Outperform and lowers the price target from $180 to $170.

MDGL

1 minute read

Madrigal Announces Debt Funding Of $250M To Back Potential US Resmetirom Launch

By Vandana Singh

Today, 12:00 PM

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) secured a $250 million term loan facility from Hercules Capital Inc (NYSE:HTGC), providing additional funding to support the expanded…

HTGC

16 minute read

Earnings Scheduled For May 9, 2022

By Benzinga Insights

Today, 12:00 PM

Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.

ACM

1 minute read

How To Attend Madrigal Pharmaceuticals Q1 2022 Earnings Conference Call

By Benzinga Insights

Today, 12:00 PM

Madrigal Pharmaceuticals (NASDAQ:MDGL) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.

MDGL

1 minute read

Madrigal Pharmaceuticals Q4 EPS $(3.78) Up From $(3.82) YoY

By Bill Haddad

Today, 12:00 PM

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(3.78) per share. This is a 1.05 percent increase over losses of $(3.82) per share from the same period last year.

MDGL

2 minute read

12 Health Care Stocks Moving In Thursday’s Intraday Session

By Benzinga Insights

Today, 12:00 PM

AIH

1 minute read

Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st at 7:00 AM ET

By Charles Gross

Today, 12:00 PM

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, plans to announce topline results from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom on Monday, January 31st, 2022.

MDGL

3 minute read

Madrigal Provides Update On Timeline For Topline Results From The Phase 3 MAESTRO-NAFLD-1 Clinical Trial Of Resmetirom

By Benzinga Newsdesk

Today, 12:00 PM

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides an update on MAESTRO-NAFLD-1, its 52-week Phase 3 multi-center, double-blind, randomized, placebo-controlled study of resmetirom in patients with

MDGL

1 minute read

Madrigal Pharmaceuticals Q3 EPS $(3.79) Down From $(3.75) YoY

By Bill Haddad

Today, 12:00 PM

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(3.79) per share. This is a 1.07 percent decrease over losses of $(3.75) per share from the same period last year.

MDGL